NCT07194772

Brief Summary

This study aimed to investigate the effects of a three-week consumption of sucralose-sweetened beverages (low-calorie sweetener) on postprandial glycemic responses in healthy adults, compared with sugar-sweetened beverages under real-world conditions. In brief, postprandial glycemic responses are used as an indicator of how your body manages blood sugar levels after consuming glucose. To explore potential mechanisms underlying any observed changes in postprandial glycemic responses, we further investigated potential alterations in gut microbiota composition and functionality, as well as plasmatic biomarkers of intestinal permeability and systemic low-grade inflammation. Finally, this project explored whether free sugars derived from a natural source (100% natural fruit juice) elicit metabolic responses that differ from those of refined sugars. Participants visited the laboratory for a preliminary screening session to assess eligibility prior to being randomly assigned to one of the three experimental groups consuming either sucralose-sweetened beverages (LCS), sucrose-sweetened beverages (SSB), or 100% natural fruit juice (FJ) at dosage approximating real-world consumption over three weeks. Participants underwent two experimental sessions (duration of 3 hours each) at the beginning and completion of the study as outlined below.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 16, 2022

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 12, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 12, 2024

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

September 18, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 26, 2025

Completed
Last Updated

September 26, 2025

Status Verified

September 1, 2025

Enrollment Period

2.2 years

First QC Date

September 18, 2025

Last Update Submit

September 18, 2025

Conditions

Keywords

low-calorie sweetenerssucralosenatural sugarsfruit juicerefined sugarssugar-sweetened beveragesLCSSSBnon-nutritive sweetenerssugar substitutesgut microbiotalow-calorie sweeteners and gut microbiotalow-calorie sweeteners and glycemic responsessucralose and gut microbiotasucralose and glycemic responses

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline in Postprandial Glycemic Responses

    Postprandial Glycemic Responses (plasma glucose concentrations) were assessed using a 2-hour 75g Oral Glucose Tolerance Test (OGTT) at baseline (day 0) and post-intervention (day 22)

    3 weeks

Secondary Outcomes (5)

  • Change from Baseline in Postprandial Insulinemic Responses

    3 weeks

  • Change from Baseline in Plasmatic Biomarkers of Intestinal Permeability

    3 weeks

  • Change from Baseline in Plasmatic Biomarkers of Systemic Low-grade Inflammation

    3 weeks

  • Change from Baseline in Fecal Concentrations of Short-Chain Fatty Acids and Branched-Chain Fatty Acids

    3 weeks

  • Change from Baseline in Alpha-diversity and Beta-diversity of the Fecal Microbiota

    3 weeks

Study Arms (3)

Sucralose-sweetened beverages (low-calorie sweetener)

EXPERIMENTAL
Other: Low-calorie sweeteners (LCS)

Sugar-sweetened beverages (refined sugars)

EXPERIMENTAL
Other: Refined sugars (SSB)

Natural fruit juice (natural sugars)

EXPERIMENTAL

100% natural orange juice

Other: Natural sugars (FJ)

Interventions

Consumption of sucralose-sweetened beverages (LCS) using doses and formulations reflecting real-world conditions. Individualized dose equivalent volume (mL) to SSB group. Average dose received of 150 mg (±30 mg) of pure sucralose per day (2.00 ± 0.23 mg/Kg BW) among participants, which is below Acceptable Daily Intake for sucralose (5 mg/Kg BW/day). LCS matched for sweetness to SSB based on the manufacturer's information.

Sucralose-sweetened beverages (low-calorie sweetener)

Consumption of sugar-sweetened beverages (SSB) using doses and formulations reflecting real-world conditions. Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada. SSB matched total free sugar concentration of 100% natural orange juice (FJ).

Sugar-sweetened beverages (refined sugars)

Consumption of natural fruit juice (100% natural orange juice) using doses and formulations reflecting real-world conditions. Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada.

Natural fruit juice (natural sugars)

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Behavioural and Metabolic Research Unit, School of Human Kinetics, Faculty of Health Sciences, University of Ottawa

Ottawa, Ontario, K1S 5S9, Canada

Location

MeSH Terms

Conditions

Glucose IntoleranceInsulin Resistance

Interventions

SSB protein, human

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesHyperinsulinism

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: randomized parallel-group design stratified by sex
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2025

First Posted

September 26, 2025

Study Start

March 16, 2022

Primary Completion

June 12, 2024

Study Completion

June 12, 2024

Last Updated

September 26, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

All de-identified individual participant data that underlie the results reported in the publication, including participants characteristics, outcomes measures (i.e., glycemic-insulinemic responses, plasmatic biomarkers of intestinal permeability and low-grade inflammation as well as microbiota outcomes) and relevant covariates will be shared. Supporting documents such as the study protocol and statistical analysis plan will also be available upon request.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning 1 year after publication and available for 2 years.
Access Criteria
Available to qualified researchers upon request (via institutional repository or upon request to the PI) and approval of a research proposal and data sharing agreement.

Locations